Skip to main content
OpenTrials
Completed

NCT Number: NCT02893410

Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients

Patients treated with oral or sub-cutaneous drugs for polycythemia vera or essential thrombocythemia completed an unique paper questionnaire in order to describe their observance, the side effects and their own appreciation of the taken drug.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Polycythemia Vera Blood Coagulation Disorders Blood Platelet Disorders Bone Marrow Diseases Bone Marrow Neoplasms Essential Thrombocythemia Hematologic Diseases Hematologic Neoplasms Hemic and Lymphatic Diseases Hemorrhagic Disorders Myeloproliferative Disorders Neoplasms Neoplasms by Site Thrombocythemia, Essential Thrombocytosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest

Brest, 29609, France

About this study

During one year, all patients with PV or ET followed in our centre, and who took a drug to treat their MPN, were identified.

The investigators submitted by mail or directly at the consultation a unique questionnaire containing 25 questions concerning patients characteristics, evaluation of observance, identification of side effects and own appreciation of the drug.

After completion of the questionnaire, the patients were identified and followed to collect new data about thrombotic events or phenotypic evolution.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with PV or ET or SMF
  • Patients who took oral or sub-cutaneous drugs to treat their MPN.
  • Patients who agreed to complete the questionnaire

Exclusion criteria

  • Patients with low risk PV or ET who do not take treatment
  • Patients unable to complete the questionnaire

Treatment and study plan

Primary outcomes

  1. Rate of adherence to drug prescription

    Time frame: At inclusion

    prospective evaluation in a one shot questionnaire given to each treated patient seen at the consultation distributed between december 2014 and december 2015

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Etude de l'Observance thérapeutique et Des Effets Secondaires Des Traitements Chez Les Patients traités Pour Polyglobulie de Vaquez et thrombocytémie Essentielle

Acronym: OUEST

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Sep 8, 2016
Registry last updated
Sep 21, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.